Imagine 14 of the world’s largest pharma companies agreeing to sit down, openly share their processes, and work collaboratively. Think it could never happen? It already has. Nearly ten years ago, some of the world’s biggest biopharmaceutical companies decided that there had to be a better way to conduct clinical trials. To create that better way, they came to Cognizant—and our Shared Investigator Platform (SIP) is the result.
As the industry's first collaborative clinical ecosystem, Cognizant SIP connects sponsors, sites and technology providers around the world to share findings, create common workflows and accelerate study start-ups. The result? New therapies get to market sooner, and more patients benefit from life-saving research.
Today, SIP boasts over 250,000 users at 32,000 trial-ready sites around the world. The platform has already made a major impact on global health—during the height of the pandemic, COVID-19 vaccines and therapeutics were developed on the platform and brought to market in record time.